A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása

B. Hunyady, Gerlei Zsuzsanna, Gervain Judit, Horváth Gábor, G. Lengyel, A. Pár, Péter Zoltán, Rókusz László, Schneider Ferenc, F. Szalay, Tornai István, Werling Klára, Makara Mihály

Research output: Article

2 Citations (Scopus)

Abstract

The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-naïve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon- free treatments and shorter therapy durations are preferred.

Original languageHungarian
Pages (from-to)3-23
Number of pages21
JournalOrvosi Hetilap
Volume159
DOIs
Publication statusPublished - febr. 1 2018

Fingerprint

Hepacivirus
Liver Diseases
Interferons
Therapeutics
Hungary
Liver Cirrhosis
Guidelines
Costs and Cost Analysis
National Health Programs
Budgets
Hepatitis C
Antiviral Agents
Organizations
Inflammation
Physicians

Keywords

  • Direct acting antiviral drug
  • Genotype
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Interferon
  • Liver cirrhosis
  • Polymerase inhibitor
  • Protease inhibitor
  • Replication complex inhibitor
  • Viral hepatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. / Hunyady, B.; Zsuzsanna, Gerlei; Judit, Gervain; Gábor, Horváth; Lengyel, G.; Pár, A.; Zoltán, Péter; László, Rókusz; Ferenc, Schneider; Szalay, F.; István, Tornai; Klára, Werling; Mihály, Makara.

In: Orvosi Hetilap, Vol. 159, 01.02.2018, p. 3-23.

Research output: Article

Hunyady, B, Zsuzsanna, G, Judit, G, Gábor, H, Lengyel, G, Pár, A, Zoltán, P, László, R, Ferenc, S, Szalay, F, István, T, Klára, W & Mihály, M 2018, 'A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása', Orvosi Hetilap, vol. 159, pp. 3-23. https://doi.org/10.1556/650.2018.31003
Hunyady, B. ; Zsuzsanna, Gerlei ; Judit, Gervain ; Gábor, Horváth ; Lengyel, G. ; Pár, A. ; Zoltán, Péter ; László, Rókusz ; Ferenc, Schneider ; Szalay, F. ; István, Tornai ; Klára, Werling ; Mihály, Makara. / A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. In: Orvosi Hetilap. 2018 ; Vol. 159. pp. 3-23.
@article{dd505ef7b4a542ea8de243a475a900f4,
title = "A hepatitis C-v{\'i}rus-fertoz{\'e}s szur{\'e}se, diagnosztik{\'a}ja, antivir{\'a}lis ter{\'a}pi{\'a}ja, kezel{\'e}s ut{\'a}ni gondoz{\'a}sa",
abstract = "The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-na{\"i}ve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon- free treatments and shorter therapy durations are preferred.",
keywords = "Direct acting antiviral drug, Genotype, Hepatitis C virus, Hepatocellular carcinoma, Interferon, Liver cirrhosis, Polymerase inhibitor, Protease inhibitor, Replication complex inhibitor, Viral hepatitis",
author = "B. Hunyady and Gerlei Zsuzsanna and Gervain Judit and Horv{\'a}th G{\'a}bor and G. Lengyel and A. P{\'a}r and P{\'e}ter Zolt{\'a}n and R{\'o}kusz L{\'a}szl{\'o} and Schneider Ferenc and F. Szalay and Tornai Istv{\'a}n and Werling Kl{\'a}ra and Makara Mih{\'a}ly",
year = "2018",
month = "2",
day = "1",
doi = "10.1556/650.2018.31003",
language = "Hungarian",
volume = "159",
pages = "3--23",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása

AU - Hunyady, B.

AU - Zsuzsanna, Gerlei

AU - Judit, Gervain

AU - Gábor, Horváth

AU - Lengyel, G.

AU - Pár, A.

AU - Zoltán, Péter

AU - László, Rókusz

AU - Ferenc, Schneider

AU - Szalay, F.

AU - István, Tornai

AU - Klára, Werling

AU - Mihály, Makara

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-naïve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon- free treatments and shorter therapy durations are preferred.

AB - The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-naïve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon- free treatments and shorter therapy durations are preferred.

KW - Direct acting antiviral drug

KW - Genotype

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Interferon

KW - Liver cirrhosis

KW - Polymerase inhibitor

KW - Protease inhibitor

KW - Replication complex inhibitor

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85042542451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042542451&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31003

DO - 10.1556/650.2018.31003

M3 - Article

C2 - 29478339

AN - SCOPUS:85042542451

VL - 159

SP - 3

EP - 23

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -